"The effect of Six months Adalimumab Treatment on Sick Leaves and retirement in Patients with rheumatoid Arthritis who are at risk of losing their ability to work".

Trial Profile

"The effect of Six months Adalimumab Treatment on Sick Leaves and retirement in Patients with rheumatoid Arthritis who are at risk of losing their ability to work".

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Adalimumab; Disease-modifying antirheumatics
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms REWARD
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Jul 2011 Additional lead trial centers ans investigators identified as reported by ClinicalTrials.gov.
    • 28 Jul 2011 Planned end date changed from 13 Aug 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov..
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top